NCT06495437尚未招募不适用
Preliminary Safety and Efficacy Study of Extracellular Vesicle Infusion in the Intervention of Age-related Phenotypes With Impaired Glucose Tolerance.
BEAUTECH0 个研究点目标入组 20 人开始时间: 2024年8月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 主要终点
- safety evaluation
研究概览
简要总结
The objective of this exploratory study was to evaluate the initial safety of human mesenchymal stem cell-derived extracellular vesicle infusion in an age-related phenotype with impaired glucose tolerance
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subjects are between 35 and 65 years old (inclusive), regardless of gender;
- •The subject's body mass index (BMI) is between 20kg/m2 and 30 kg/m2;
- •The subjects were assessed by the clinical expert group as having abnormal glucose tolerance (PPG 7.8-11.0mmol/L 2h postprandial);
- •Subjects voluntarily participate in this clinical study and sign a written informed consent.
排除标准
- •The subject has a severe allergy or is allergic to any component used in cell culture;
- •The subject has used or is using drugs that affect glucose metabolism (such as glucocorticoids, tricyclic antidepressants, etc.) within 1 month;
- •The subjects have chronic diseases such as diabetes and hypertension (very high-risk group) which have not been effectively controlled after treatment;
- •Subjects with severe cardiovascular and cerebrovascular diseases: patients with a history of decompensated cardiac insufficiency (NYHA grade Ⅲ or Ⅳ), myocardial infarction or cerebral infarction, or cerebral hemorrhage within 6 months before screening;
- •The subjects had abnormal liver function (ALT and/or AST≥ 2.5 times the upper limit of normal), significant abnormal renal function, male serum creatinine ≥1.5mg/dl, female serum creatinine ≥1.4mg/dl; 6, the subject's HIV antibody, hepatitis B surface antigen, hepatitis C antibody, syphilis test positive, hepatitis B virus DNA quantitative > the upper limit of normal test unit;
- •7. Subjects with other serious systemic diseases affecting the study, including malignant tumors, nervous central system, blood system, digestive system, endocrine system, respiratory system, infectious diseases, etc.; (8) Drug or alcohol abuse (subjects who consumed >2 alcoholic beverages per day or >14 alcoholic beverages per week (one alcoholic beverage is defined as 150ml of wine, 350ml of beer, or 50ml of 80% (40 proof) spirits); Or drug abusers;
- •Pregnant and lactating women; Have a pregnancy plan in the next 2 years (including the spouse's pregnancy plan); Refusal to use effective contraception;
- •Exclude intracranial lesions and early lung tumors;
- •Used stem cell (exosome) therapy or participated in stem cell (exosome) clinical researchers 3 months before screening; Clinical investigators who have participated in drugs within 3 months before screening;
- •High risk groups with Padua score ≥4 or Caprini score ≥5;
- •The subject has a history of major surgery within the past six months or is expected to have surgery within six months;
- •There are other conditions that the researcher considers inappropriate to participate in this clinical study.
结局指标
主要结局
safety evaluation
时间窗: 0-12 weeks
Incidence of adverse events from baseline to the end of 12 weeks. The frequency and frequency of adverse events (including injection site reactions) were analyzed. The number of cases and cases of adverse events, adverse reactions, AES leading to fall off, SAE, aes of different severity, AES leading to death were calculated respectively, and a detailed list was provided. The incidence rate was calculated using the number of people in each safety dataset as the denominator, and if necessary, Chi-square test or Fisher exact probability method was used for inter-group comparison.
次要结局
- Effectiveness evaluation(0-12 weeks)
研究者
相似试验
Unknown
1 期
Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus PatientsType 1 Diabetes MellitusNCT03484741Van Hanh General Hospital15
Unknown
1 期
Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1)Osteoarthritis, KneeNCT05060107Francisco Espinoza10
已完成
1 期
Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus ErythematosusLupus Erythematosus SystemNCT03171194Medical University of South Carolina6
撤回
1 期
Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine ScarsUterine ScarNCT03181087Maternal and Child Health Hospital of Foshan
已完成
1 期
A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung TransplantationBronchiolitis ObliteransLung TransplantationNCT01175655The Prince Charles Hospital10